You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

recurrent and/or metastatic

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Gland, Salivary Gland Cancers Trial in Houston (Sacituzumab Govitecan)

Not yet recruiting
  • Gland
  • Salivary Gland Cancers
  • Sacituzumab Govitecan
  • Houston, Texas
    M D Anderson Cancer Center
May 22, 2023

Cancer: Recurrent and/or Metastatic Solid Tumours Trial in Edmonton (CCI-001)

Recruiting
  • Cancer: Recurrent and/or Metastatic Solid Tumours
  • Edmonton, Alberta, Canada
    Cross Cancer Institute
Jul 12, 2022

Head Neck Cancer Trial in Boston (Oral Decitabine, Durvalumab)

Active, not recruiting
  • Head and Neck Cancer
  • Boston, Massachusetts
    Massachusetts General Hospital
Oct 30, 2022

Cutaneous Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma of the Head and Neck Trial in Tucson, Tampa

Terminated
Has Results
  • Cutaneous Squamous Cell Carcinoma
  • Cutaneous Squamous Cell Carcinoma of the Head and Neck
  • Tucson, Arizona
  • +1 more
Nov 2, 2022

Carcinoma, Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Trial (NRC-2694-A, Paclitaxel)

Recruiting
  • Carcinoma
  • Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
  • Los Angeles, California
  • +2 more
Nov 23, 2022

Cadonilimab in Recurrent or Metastatic Cervical Cancer

Not yet recruiting
  • Recurrent or Metastatic Cervical Cancer
  • (no location specified)
Nov 23, 2023

HER2-PositiveRecurrent or Metastatic Breast Cancer Trial (SHR-A1811 Injection, SHR-A1811 Injection ; Pertuzumab Injection,

Not yet recruiting
  • HER2-PositiveRecurrent or Metastatic Breast Cancer
  • SHR-A1811 Injection
  • +2 more
  • (no location specified)
Sep 21, 2023

Head and Neck Squamous Cell Carcinoma (HNSCC) Trial in Seoul (Nivolumab)

Active, not recruiting
  • Head and Neck Squamous Cell Carcinoma (HNSCC)
  • Seoul, Korea, Republic of
    Yonsei Severance Hospital
Jan 27, 2022

Metastatic Head-and-neck Squamous-cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma Trial (Ficlatuzumab,

Not yet recruiting
  • Metastatic Head-and-neck Squamous-cell Carcinoma
  • Recurrent Head and Neck Squamous Cell Carcinoma
  • Ficlatuzumab
  • +2 more
  • (no location specified)
Sep 26, 2023

Locally Advanced or Recurrent Metastatic HER-2 Negative Breast Cancer Trial in Shanghai (BL-B01D1, SI-B003)

Not yet recruiting
  • Locally Advanced or Recurrent Metastatic HER-2 Negative Breast Cancer
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Sep 12, 2023

Recurrent or Metastatic Colorectal Cancer Trial (Nelmastobart and Capecitabine)

Not yet recruiting
  • Recurrent or Metastatic Colorectal Cancer
  • Nelmastobart and Capecitabine
  • (no location specified)
Aug 6, 2023

Gynecological Malignancies Trial in Beijing (BL-M07D1)

Not yet recruiting
  • Gynecological Malignancies
  • Beijing, Beijing, China
    Cancer Hospital, Chinese Academy of Medical Sciences
Nov 15, 2023

Nasopharyngeal Carcinoma, Immune Checkpoint Inhibitors Trial (Cadonilimab, Gemcitabine, Cisplatin)

Not yet recruiting
  • Nasopharyngeal Carcinoma
  • Immune Checkpoint Inhibitors
  • (no location specified)
Jun 1, 2023

First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer Trial (KN026, HB1801, Pertuzumab)

Not yet recruiting
  • First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer
  • (no location specified)
Apr 20, 2023

Cervical Cancer, HPV-Related Carcinoma, HPV-Related Malignancy Trial run by the Precigen, Inc (PRGN-2009 plus Pembrolizumab,

Not yet recruiting
  • Cervical Cancer
  • +2 more
  • PRGN-2009 plus Pembrolizumab
  • Pembrolizumab alone
  • Bethesda, Maryland
    National Institute of Health
Nov 27, 2023

Solid Tumors Trial in Guangzhou (MASCT-I injection)

Completed
  • Solid Tumors
  • MASCT-I injection
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
May 25, 2023

Head and Neck Squamous Cell Carcinoma Trial (Zanzalintinib, Zanzalintinib-matched Placebo, Pembrolizumab)

Not yet recruiting
  • Head and Neck Squamous Cell Carcinoma
  • (no location specified)
Oct 9, 2023

Squamous Cell Carcinoma Trial (MK-3475A)

Not yet recruiting
  • Squamous Cell Carcinoma
  • MK-3475A
  • (no location specified)
Sep 11, 2023

Solid Tumor Trial in Wuhan (HPV-T, Interleukin-2)

Recruiting
  • Solid Tumor
  • Wuhan, Hubei, China
    Wuhan Union Hospital
May 31, 2023

Adenoid Cystic Carcinoma of the Head and Neck Trial (OBT076, Balstilimab)

Not yet recruiting
  • Adenoid Cystic Carcinoma of the Head and Neck
  • (no location specified)
Jul 3, 2023

HER2-positive Recurrent or Metastatic Malignant Solid Tumor Trial in Zhengzhou (Recombinant Humanized Bispecific Monoclonal

Recruiting
  • HER2-positive Recurrent or Metastatic Malignant Solid Tumor
  • Recombinant Humanized Bispecific Monoclonal Antibody MBS301
  • Zhengzhou, China
    Henan Cancer Hospital
Nov 9, 2022

Esophageal Cancer Trial (Tislelizumab, Radiation, Paclitaxel)

Not yet recruiting
  • Esophageal Cancer
  • (no location specified)
Nov 18, 2022

Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma, Stage IV Nasopharyngeal Carcinoma AJCC v8 Trial

Not yet recruiting
  • Metastatic Nasopharyngeal Carcinoma
  • +2 more
  • Nivolumab
  • +5 more
  • (no location specified)
Aug 21, 2023

Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Stage IV Major Salivary Gland Cancer AJCC v8 Trial in

Recruiting
  • Metastatic Salivary Gland Carcinoma
  • +5 more
  • Pembrolizumab
  • Pemetrexed Disodium
  • Scottsdale, Arizona
  • +2 more
Mar 15, 2022

Salivary Duct Carcinoma Trial in Nijmegen (Goserelin 10.8 mg, Bicalutamide 50 mg, Dutasteride 0.5 mg)

Not yet recruiting
  • Salivary Duct Carcinoma
  • Goserelin 10.8 mg
  • +2 more
  • Nijmegen, Gelderland, Netherlands
    Radboudumc
Aug 23, 2022